Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 6/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | MEN1 | O00255 | 3/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | HTT | P42858 | 2/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | PRKDC | P78527 | 2/20 | 0.49 |
| ▸ | PKM | P14618 | 2/20 | 0.49 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.49 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28377534 | 0.89 | ALDH1A1 (0.46) | LMNAMAPTALDH1A1MEN1KMT2A | |
| SCHEMBL17121096 | 0.84 | ALDH1A1 (0.52) | LMNAMAPTALDH1A1MEN1KMT2A | |
| SCHEMBL578242 | 0.83 | L3MBTL3 (0.54) | ALDH1A1KDM4E | |
| SCHEMBL381631 | 0.83 | ALDH1A1 (0.48) | LMNAMAPTALDH1A1MEN1KMT2A | |
| SCHEMBL9093746 | 0.82 | LMNA (0.71) | LMNAMAPTALDH1A1MEN1KMT2A | |
| SCHEMBL1745699 | 0.81 | ALDH1A1 (0.52) | LMNAMAPTALDH1A1MEN1KMT2A | |
| SCHEMBL10317320 | 0.81 | ALDH1A1 (0.52) | LMNAMAPTALDH1A1MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL27043157 | 0.81 | ALDH1A1 (0.52) | LMNAMAPTALDH1A1MEN1KMT2A | |
| SCHEMBL875323 | 0.80 | KMO (0.55) | LMNAMAPTALDH1A1MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL1954079 | 0.79 | ALDH1A1 (0.55) | LMNAMAPTALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 859 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122079924-A | Camphoryl benzothiazole ratio type fluorescent probe for detecting hydrazine and preparation method and application thereof | — | 2026-05-26 | — | — | CN | claimed |
| CN-122079924-A | Camphoryl benzothiazole ratio type fluorescent probe for detecting hydrazine and preparation method and application thereof | — | 2026-05-26 | — | — | CN | disclosed |
| CN-122079924-A | Camphoryl benzothiazole ratio type fluorescent probe for detecting hydrazine and preparation method and application thereof | — | 2026-05-26 | — | — | CN | disclosed |
| EP-4745117-A1 | NOVEL INDENONE DERIVATIVE AND USE THEREOF | Amyloid Solution Inc. (KR) | 2026-05-20 | — | — | EP | disclosed |
| CN-121673249-A | Fluorescent emission material and preparation method thereof | 阜阳欣奕华制药科技有限公司 | 2026-03-17 | — | — | CN | disclosed |
| US-12552801-B2 | Indazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2026-02-17 | — | — | US | disclosed |
| EP-4692072-A1 | PHOTOCHROMIC COMPOUND, PROPARGYL ALCOHOL COMPOUND, CURABLE COMPOSITION, OPTICAL ARTICLE, LENS, AND SPECTACLES | TOKUYAMA CORPORATION (JP) | 2026-02-11 | — | — | EP | disclosed |
| WO-2025264954-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMACEUTICALS, INC. (US) | 2025-12-26 | — | — | WO | disclosed |
| EP-4663630-A1 | NOVEL BENZIMIDAZOLONE DERIVATIVE COMPOUND AS AUTOTAXIN INHIBITOR | LG Chem, Ltd. (KR) | 2025-12-17 | — | — | EP | disclosed |
| EP-4655288-A1 | PHD INHIBITORS | Oxford University Innovation Limited (GB) | 2025-12-03 | — | — | EP | disclosed |
| US-20040014755-A1 | Rho-kinase inhibitors | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2004-01-22 | — | — | US | disclosed |
| WO-2003104227-A1 | 2-HETEROARYL CARBOXAMIDES | BAYER HEALTHCARE AG (DE) | 2003-12-18 | — | — | WO | disclosed |
| WO-2003078431-A1 | AZA-BICYCLIC N-BIARYLAMIDES WITH AFFINITY FOR THE ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR | BAYER HEALTHCARE AG (DE) | 2003-09-25 | — | — | WO | disclosed |
| WO-2003059913-A1 | ROH-KINASE INHIBITORS | BAYER HEALTHCARE AG (DE) | 2003-07-24 | — | — | WO | disclosed |
| EP-0832082-B1 | N-HETEROARYL-PYRIDINESULFONAMIDE DERIVATIVES AND THEIR USE AS ENDOTHELIN ANTAGONISTS | ASTRAZENECA AB (SE) | 2001-11-21 | — | — | EP | disclosed |
| US-6258817-B1 | PRODRUGS, HYPOTENSIVE AGENTS AND CARDIOVASCULAR DISORDERS | ZENECA LTD. (GB) | 2001-07-10 | — | — | US | disclosed |
| US-6060475-A | Substituted pyrazin-2-yl-sulphonamide-(3-pyridyl) compounds and uses thereof | ZENECA LIMITED (GB) | 2000-05-09 | — | — | US | disclosed |
| US-5866568-A | ENDOTHELIN RECEPTOR ANTAGONIST ACTIVITY | ZENECA LIMITED (GB) | 1999-02-02 | — | — | US | disclosed |
| EP-0832082-A1 | N-HETEROARYL-PYRIDINESULFONAMIDE DERIVATIVES AND THEIR USE AS ENDOTHELIN ANTAGONISTS | ZENECA LIMITED (GB) | 1998-04-01 | — | — | EP | disclosed |
| WO-1996040681-A1 | N-HETEROARYL-PYRIDINESULFONAMIDE DERIVATIVES AND THEIR USE AS ENDOTHELIN ANTAGONISTS | ZENECA LIMITED (GB) | 1996-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014755-A1 | Rho-kinase inhibitors | CIT, ROCK1, ROCK2 | LMNA 3659/4885MAPT 2039/4885ALDH1A1 3561/4885 |
| US-12552801-B2 | Indazole derivatives | EGFR, ABL1, ERBB3 | LMNA 4809/4885MAPT 3358/4885ALDH1A1 1341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.